Torrent Pharma: Cost controls not enough, recovery in key markets crucial

Torrent Pharmaceuticals’ impressive July-September quarter (Q2) performance lends confidence to its strength in the domestic arena. Continued resilience in chronic therapies and a rebound in acute therapy sales have led to the domestic business (nearly half of overall) grow 7 per cent year-on-year —  4.1 per cent sequentially — outperforming the Indian pharma market by 1 percentage point in the September quarter.

Chronic and sub-chronic therapies, accounting for 77 per cent of India sales, are outperforming the domestic market, say analysts.

The growth also continues to be driven by price hikes taken by Torrent. Analysts say similar price hike-led growth can be